ERBB2 and breast neoplasm: The human patient cohort was composed of 10 basal, 1 claudin-low (CLDN-low), 9 luminal B and 4 HER2-enriched (HER2-E) breast tumours based on PAM50 expression subtyping (Supplementary Data 1).